Genmab Looks Past Turnaround to Takeoff

Dow Jones
11/16

1026 GMT - Genmab's trio of positive late-stage clinical trials mean the Danish biotech company is moving away from a turnaround toward its takeoff, UBS analysts say in a research note. "Genmab has achieved something that is rarely seen in the pharma industry--a highly successful [research-and-development] turnaround," the analysts say. In October, the company reported three very strong late-stage data sets that justified its recent stock rally as each of the drugs has potential to generate more than $7 billion in annual revenue, according to UBS. "We think this is only the start," the analysts add. UBS raises its target price on Genmab to 4,900 Danish kroner from 3,100 kroner. Shares trade 2.4% higher at 3,532 kroner, having gained 74% since the start of 2026.

 

应版权方要求,你需要登录查看该内容

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10